Specialists are questioning the feasibility of three U.S. factories being built to rapidly turn out drugs needed after an attack or disaster, Nature reports.
Certain analysts argued that few useful antidotes are currently available for responding to the types of biological and chemical events envisioned by the production facilities under preparation in Texas, North Carolina and Maryland, the journal reported on Tuesday. Observers also cast doubt on the utility of next-generation smallpox vaccines, as well as other drugs that may be produced at the so-called Centers for Innovation in Advanced Development and Manufacturing.
The United States is relatively unlikely to face a chemical or biological strike for which the factories would prove useful, argued Richard Ebright, a molecular biologist with Rutgers University. The Texas plant is slated to begin generating its first vaccine in the middle of this year, and federal officials plan in the next quarter-century to spend up to $2 billion on medical treatments from that single facility.
Philip Russell, a former biodefense adviser for the George W. Bush administration, suggested the United States should have built just one such production site for civilian and military needs, in line with a 2008 recommendation by the Pentagon’s Defense Advanced Research Projects Agency.
“Rather than one good operation that meets the government’s needs, we got three operations that spread the money around,” Russell said of the $440 million initiative, launched in 2012 by the Health and Human Services Department.
The current plan’s backers, meanwhile, argued that operating several manufacturing plants would provide a fallback if one is compromised by a strike or release of hazardous material.
In addition to the three sites overseen by Health and Human Services, the Defense Department is constructing a $136 million factory in Florida to generate smaller quantities of biodefense products for armed-forces use. That site is expected to operate at an annual cost of $20 million following its scheduled launch in 2015.
What We're Following See More »
Howard Dean, the former Vermont governor and Democratic National Committee chair, announced he's pulling out of the running to regain the chairman's post. Dean "announced in a pre-recorded video to a conference of state Democratic chairs that he would step aside to allow for a new face to lead the party as it seeks to rebuild."
"Once again, businessman and philanthropist David M. Rubenstein has come through for the National Park Service. This time, he's pledged funding needed to modernize the Washington Monument's elevator-- but the monument will remain closed until 2019 while repairs and improvements are underway. Rubenstein's donation of between $2-3 million, announced Friday, will correct those ongoing elevator issues, which have shuttered the monument since August 17."
The National Defense Authorization Act passed the House this morning by a 375-34 vote. The bill, which heads to the Senate next week for final consideration, would fund the military to the tune of $618.7 billion, "about $3.2 billion more than the president requested for fiscal 2017. ... The White House has issued a veto threat on both the House and Senate-passed versions of the bill, but has not yet said if it will sign the compromise bill released by the conference committee this week."
Bill Schuette, Michigan's attorney general, has filed a lawsuit on behalf of the state to halt the recount of the state's voting results. The recount was elected by Green Party candidate Jill Stein. Schuette says the recount shouldn't occur because Stein cited no evidence of voter fraud or tabulation error.
"Republicans have elected Rep. Greg Walden (R-OR) the next chairman of the powerful House Energy and Commerce Committee. Walden defeated Reps. John Shimkus (R-IL) and Joe Barton (R-TX), the former committee chairman, in the race for the gavel" to succeed Michgan's Fred Upton.